Can I Take Green Tea Extract (EGCG) with Jatenzo?

What Is Jatenzo and Why Does the Liver Matter?

Jatenzo is the first FDA-approved oral testosterone undecanoate (TU) formulation designed for adult males with hypogonadism caused by a medical condition [1]. Unlike older alkylated oral androgens, Jatenzo uses a self-emulsifying drug delivery system that absorbs testosterone through intestinal lymphatics rather than first-pass hepatic metabolism [2]. That design substantially reduces direct hepatic exposure compared with 17-alpha-alkylated androgens such as methyltestosterone, which is why Jatenzo carries no specific liver-toxicity black-box warning.

Still, the liver does process testosterone undecanoate to a degree. Monitoring of hepatic function is standard clinical practice for any androgen therapy [3].

How Jatenzo Is Absorbed

The lymphatic absorption pathway means Jatenzo must be taken with a meal containing fat. A fat-containing meal of at least 20 grams is required; the prescribing information for Jatenzo states that Cmax and AUC drop sharply when the capsule is taken fasted [1]. This fat-dependent absorption is also relevant when thinking about green tea extract timing, because GTE is more hepatotoxic when taken on an empty stomach [4].

Baseline Liver Monitoring for Jatenzo

The Endocrine Society's 2018 clinical practice guideline for male hypogonadism recommends measuring hematocrit, PSA, and a metabolic panel including liver enzymes at baseline and at 3 and 12 months after initiating androgen therapy [3]. A 2023 update from the American Urological Association echoes routine monitoring at similar intervals [5]. Any supplement with an independent hepatotoxicity signal adds incremental burden to those monitoring targets.

What Is Green Tea Extract (EGCG) and What Are Its Known Risks?

Green tea extract is a concentrated supplement derived from Camellia sinensis leaves. Most standardized products deliver 45 to 95% catechins, with EGCG (epigallocatechin gallate) as the dominant fraction, typically representing 50 to 75% of total catechins [6]. Supplemental doses range widely, from 100 mg to over 1,000 mg EGCG per day, far exceeding what is consumed in brewed tea (roughly 50 to 100 mg per cup) [7].

EGCG has a reasonable evidence base for modest effects on body weight, lipids, and metabolic markers at low to moderate doses. A 2020 Cochrane-adjacent systematic review of 27 randomized trials found green tea preparations produced a mean 1.78 kg weight reduction versus placebo, though effect sizes were small [8]. The risks, however, scale with dose.

The Hepatotoxicity Signal

The U.S. Pharmacopeia (USP) Dietary Supplement Information Expert Committee conducted a formal causality assessment and concluded that GTE is "possibly causally associated" with liver injury, particularly at doses above 800 mg EGCG per day or when taken fasted [4]. A 2020 systematic review in the journal Nutrients identified 80 published case reports of GTE-associated hepatotoxicity, with the majority involving products providing more than 700 mg EGCG daily [9]. Several of those cases met Roussel Uclaf Causality Assessment Method (RUCAM) criteria for probable or definite drug-induced liver injury (DILI) [9].

The European Food Safety Authority (EFSA) concluded in 2018 that oral GTE doses above 800 mg EGCG per day raise safety concerns, and that fasted intake amplifies risk regardless of dose [10].

Fasted vs. Fed Intake Makes a Measurable Difference

A crossover pharmacokinetic study (N=30) published in Molecular Nutrition and Food Research found that EGCG Cmax was 3.4-fold higher when consumed in a fasted state versus with a standardized breakfast [11]. Higher plasma EGCG concentrations correlate with oxidative stress and mitochondrial dysfunction in hepatocytes in vitro [12]. Because Jatenzo must itself be taken with food, a patient who takes GTE at the same meal gets some incidental fed-state protection, but that protection disappears if a second GTE dose is taken between meals.

Pharmacokinetic Interaction: CYP3A4 and P-Glycoprotein

Jatenzo's primary metabolic pathway runs through CYP3A4 [1]. Testosterone is converted to its active and inactive metabolites by this enzyme, and drugs or supplements that inhibit or induce CYP3A4 directly change circulating testosterone levels.

EGCG as a CYP3A4 Modulator

EGCG inhibits CYP3A4 in vitro, though the clinical magnitude at typical supplement doses remains uncertain. A 2004 study in Drug Metabolism and Disposition demonstrated that EGCG inhibited CYP3A4-mediated midazolam hydroxylation with a Ki of approximately 8.1 micromolar [13]. A subsequent human pharmacokinetic study using green tea extract (800 mg/day for 14 days) showed a statistically significant 24% increase in the AUC of midazolam, a standard CYP3A4 probe substrate, in healthy volunteers (P<0.05) [14]. If a similar inhibitory effect applies to testosterone metabolism, the result could be elevated androgen exposure, with downstream risks including erythrocytosis and blood-pressure elevation. Jatenzo's prescribing label already carries an FDA black-box warning about blood-pressure increases [1].

P-Glycoprotein Effects

EGCG also inhibits P-glycoprotein (P-gp), an efflux transporter that affects the bioavailability of multiple drugs [15]. Testosterone undecanoate absorption via intestinal lymphatics may involve efflux transporters to a minor degree. The clinical relevance of P-gp inhibition by EGCG on Jatenzo pharmacokinetics specifically has not been studied, but the mechanistic concern is real.

What a CYP3A4 Inhibitor Does to Testosterone Exposure

Any meaningful CYP3A4 inhibition raises the area under the testosterone concentration-time curve. The Jatenzo prescribing information notes that strong CYP3A4 inhibitors such as ketoconazole can substantially increase testosterone AUC, requiring dose adjustment [1]. GTE is a weaker inhibitor than ketoconazole, but a 20 to 30% AUC increase is not trivially small when patients are already titrating to an individualized Jatenzo dose.

Pharmacodynamic Interaction: Additive Hepatotoxicity

Even setting aside enzyme kinetics, both Jatenzo and high-dose GTE place metabolic demands on hepatocytes. This overlap is a pharmacodynamic interaction, meaning it occurs at the level of organ-level physiology rather than drug metabolism.

Androgen Therapy and Liver Enzymes

A 2021 review in the Journal of Clinical Endocrinology and Metabolism noted that while modern oral testosterone formulations avoiding 17-alpha alkylation carry much lower hepatotoxicity than older agents, mild transient ALT elevations are still observed in a minority of patients [16]. Across clinical trials of oral TU in the MPOWER and Jatenzo registration programs, ALT elevations above three times the upper limit of normal occurred in roughly 2% of participants [1, 17].

Additive Stress on Hepatocytes

Adding a supplement with its own hepatotoxicity signal to a drug with even a small independent signal increases the probability of crossing clinical injury thresholds. A 2022 Drug Safety paper modeling additive DILI risk argued that co-exposure to two agents each with RUCAM-confirmed associations with liver injury multiplies injury probability in a greater-than-additive fashion in susceptible individuals [18]. Patients with pre-existing fatty liver disease, elevated baseline ALT, or heavy alcohol use face particularly elevated risk.

Practical Risk Stratification for Patients Already Taking Both

Not every patient taking Jatenzo and GTE simultaneously is in immediate danger. Risk level depends on EGCG dose, intake state, baseline liver health, and how long the combination has been used.

Lower-Risk Profile

A patient with normal baseline liver enzymes, taking a GTE product providing <400 mg EGCG per day, consuming it exclusively with meals, avoiding alcohol, and having liver function tests (LFTs) checked every 3 months is likely operating in a manageable risk window. Low-dose GTE (<400 mg EGCG/day) in fed conditions did not produce hepatotoxic signals in 12-week supplementation studies [7].

Higher-Risk Profile

Risk climbs sharply for patients using GTE doses above 800 mg EGCG daily, taking GTE on an empty stomach, having a baseline ALT already above the normal range, using other hepatically metabolized drugs, or drinking alcohol regularly. These patients should discontinue GTE or at minimum pause it until LFTs are verified normal.

Step-by-Step Monitoring Protocol

1. Check ALT, AST, and total bilirubin before starting or continuing either agent.
2. Repeat LFTs at 4 to 6 weeks if starting or increasing GTE dose.
3. Follow the Endocrine Society's recommended 3-month and 12-month monitoring schedule for androgen therapy regardless of GTE use [3].
4. Discontinue GTE immediately if ALT exceeds two times the upper limit of normal on two consecutive measurements taken 2 weeks apart.
5. If ALT exceeds three times the upper limit of normal on a single measurement, hold Jatenzo and contact your prescriber the same day [1].

What to Tell Your Prescriber

Patients often do not volunteer supplement use, and prescribers often do not ask. A 2019 JAMA Internal Medicine survey found that 69% of supplement users did not disclose use to their physician [19]. That gap is clinically significant when the supplement in question has a documented hepatotoxicity signal and CYP3A4 inhibitory activity.

Information to Bring to Your Appointment

Tell your prescriber the brand name of the GTE product, the labeled EGCG content per serving, the number of servings per day, and whether you take it with food or on an empty stomach. Bring the supplement bottle or a photo of the label. Prescribers can then cross-reference the EGCG dose against published thresholds and decide whether to order liver labs sooner than the standard schedule.

When to Stop GTE Without Waiting

Stop GTE immediately and call your prescriber if you develop any of the following: right-upper-quadrant abdominal pain, dark urine, jaundice (yellowing of skin or eyes), unusual fatigue lasting more than 3 days, or nausea not explained by another cause. These are recognized early symptoms of drug-induced liver injury [20].

Dose and Timing Considerations

If a prescriber and patient agree that low-dose GTE provides meaningful benefit (for example, as part of a metabolic syndrome management strategy alongside Jatenzo), the following dose-timing principles reduce risk:

Always take GTE with the same fat-containing meal required for Jatenzo. Taking GTE with food reduces peak EGCG plasma concentration by roughly 3-fold compared with fasted intake [11]. Keep total daily EGCG below 400 mg. Products providing 200 to 300 mg EGCG per serving once daily with the morning Jatenzo dose represent the lowest plausible risk configuration. Do not take a second GTE dose between meals even if the product label suggests split dosing.

Avoid GTE products that are marketed as "high-potency" or "mega-dose" formulations, which routinely exceed 800 mg EGCG per serving. These products generated the majority of hepatotoxicity case reports [9].

Summary of Evidence Quality

The evidence linking GTE to hepatotoxicity is based on case series and pharmacokinetic studies rather than large randomized controlled trials. The CYP3A4 inhibition data for EGCG comes primarily from in vitro experiments and one small human probe-substrate study (N=12) [14]. The pharmacodynamic additive-hepatotoxicity concern is mechanistically plausible but lacks a dedicated clinical trial in Jatenzo users specifically. That evidence gap does not mean the combination is safe. It means the risk has not been quantified with precision, and clinical caution is appropriate until better data exist.